Skip to main content

A Multi¿Center, Open¿Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

September 1, 2016

End Date

August 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

September 1, 2016

End Date

August 31, 2022